R-carvedilol, a potential new therapy for Alzheimer’s disease
Open Access
- 24 November 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1062495
Abstract
For decades, the amyloid cascade hypothesis has been the leading hypothesis in studying Alzheimer’s disease (AD) pathology and drug development. However, a growing body of evidence indicates that simply removing amyloid plaques may not significantly affect AD progression. Alternatively, it has been proposed that AD progression is driven by increased neuronal excitability. Consistent with this alternative hypothesis, recent studies showed that pharmacologically limiting ryanodine receptor 2 (RyR2) open time with the R-carvedilol enantiomer prevented and reversed neuronal hyperactivity, memory impairment, and neuron loss in AD mouse models without affecting the accumulation of ß-amyloid (Aβ). These data indicate that R-carvedilol could be a potential new therapy for AD.Keywords
This publication has 94 references indexed in Scilit:
- An Update of Animal Models of Alzheimer Disease with a Reevaluation of Plaque DepositionsExperimental Neurobiology, 2013
- Ryanodine Receptor Blockade Reduces Amyloid-β Load and Memory Impairments in Tg2576 Mouse Model of Alzheimer DiseaseJournal of Neuroscience, 2012
- Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer’s diseaseProceedings of the National Academy of Sciences of the United States of America, 2012
- Altered ryanodine receptor expression in mild cognitive impairment and Alzheimer's diseaseNeurobiology of Aging, 2012
- Carvedilol as a potential novel agent for the treatment of Alzheimer's diseaseNeurobiology of Aging, 2011
- Carvedilol and its new analogs suppress arrhythmogenic store overload–induced Ca2+ releaseNature Medicine, 2011
- Effects of Cardiovascular Medications on Rate of Functional Decline in Alzheimer DiseaseThe American Journal of Geriatric Psychiatry, 2008
- Pharmacology of carvedilolThe American Journal of Cardiology, 2004
- Neuroprotective effects of carvedilol, a new antihypertensive agent, in cultured rat cerebellar neurons and in gerbil global brain ischemia.Stroke, 1992
- The interaction of the enantiomers of carvedilol with α1‐ and β1‐adrenoceptorsChirality, 1989